Freedom of Information Team
Department of Health and Social Care
39 Victoria Street
London SW1H 0EU
Ms Louise Bicknell
By email to: email@example.com
15 December 2022
Dear Ms Bicknell, Freedom of Information Request Reference FOI-1428148
Thank you for your request dated 30 November to the Department of Health and Social
Care (DHSC), a copy of which can be found in the accompanying annex.
Your request has been handled under the Freedom of Information Act 2000.
DHSC does not hold information relevant to your request.
This response is based on searches of email accounts and inboxes.
If you are not satisfied with the handling of your request, you have the right to appeal by
asking for an internal review. This should be sent to firstname.lastname@example.org
to the address at the top of this letter and be submitted within two months of the date of
Please remember to quote the reference number above in any future communication.
If you are not content with the outcome of your internal review, you may complain directly
to the Information Commissioner’s Office (ICO). Generally, the ICO cannot make a
decision unless you have already appealed our original response and received our internal
review decision. You should raise your concerns with the ICO within three months of your
last meaningful contact with us.
Guidance on contacting the ICO can be found at https://ico.org.uk/global/contact-us
information about making a complaint can be found at https://ico.org.uk/make-a-complaint.
Freedom of Information Team email@example.com
From: Louise Bicknell firstname.lastname@example.org
Sent: 29 November 2022 16:15
To: FreedomofInformation email@example.com
Subject: Freedom of Information request - Communications about Evusheld between
Professor James Palmer and the Antivirals and Therapeutics Taskforce
Dear Department of Health and Social Care,
For the period 1 April 2022 to 6 September 2022
All direct communications between Professor James Palmer with the Antivirals and
Therapeutics Taskforce (should this have its own email address or electronic identity) in
which Evusheld (i.e. the combination of Tixagevimab and cilgavimab, AZD7742 or any
other name that is used by the DHSC for this) is mentioned, whether by email or other